| NTLA | 8-K | mixed | 6/10 | Intellia Therapeutics reported its Q4 and full-year 2025 financial results, highlighting a reduction in net loss to $95. | Feb 26, 2026 |
| TWST | CLUSTER | bearish | 6/10 | Six insiders at Twist Bioscience Corp, including the CEO, COO, CFO, and other executives, sold shares in a coordinated o | Feb 26, 2026 |
| TXG | CLUSTER | bearish | 6/10 | Three 10x Genomics insiders, including CEO Serge Saxonov and CFO Adam Taich, sold shares in a coordinated open-market tr | Feb 26, 2026 |
| TWST | CLUSTER | bearish | 7/10 | Four corporate insiders at Twist Bioscience Corp, including the CEO, COO, CFO, and another executive, sold shares in a c | Feb 26, 2026 |
| TXG | CLUSTER | bearish | 6/10 | Three corporate insiders at 10x Genomics, Inc. (TXG) — including the CEO and CFO — sold shares in a coordinated open-mar | Feb 26, 2026 |
| TXG | CLUSTER | bearish | 6/10 | Three insiders at 10x Genomics, Inc. (TXG) sold shares in a coordinated open-market transaction on February 23, 2026, in | Feb 25, 2026 |
| TXG | CLUSTER | bearish | 5/10 | Two insiders at 10x Genomics, Inc. (TXG) sold shares in the past week, including CFO Adam Taich who sold nearly $167K wo | Feb 25, 2026 |
| TWST | CLUSTER | bearish | 6/10 | Three insiders at Twist Bioscience Corp sold shares in a coordinated open-market transaction on February 23, 2026, inclu | Feb 25, 2026 |
| RXRX | 8-K | bullish | 8/10 | Recursion reported strong financial results for Q4 and full year 2025, highlighted by a 689% year-over-year increase in | Feb 25, 2026 |
